TradingNote
Gurus

Top Investors

Warren BuffettCathie WoodLi LuRay DalioBill AckmanView all Top Investors
Archive
Industry

AI & Compute

Semiconductors & AcceleratorsCloud & AI PlatformsData Center & NetworkingView all AI & Compute
Research

ABVC

ABVC BioPharma, Inc.

Investor Moves

InvestorPortfolio ValuePortfolio ChangePosition ChangeAvg Buy PriceCurrent Price
Jim SimonsRenaissance Technologies
$92k95.1k shares
TrimQ1 2026
$151k
$1.65
$1.39
Ken GriffinCitadel Advisors
$-118.3K
ExitQ1 2026
$118k
$1.65
$1.39
Jim SimonsRenaissance Technologies
$243k114.3k shares
TrimQ4 2025
$93k
$2.68
$1.39
Ken GriffinCitadel Advisors
$118k55.5k shares
AddQ4 2025
$71k
$2.68
$1.39
Jim SimonsRenaissance Technologies
$243.1K
AddQ3 2025
$243k
$3.07
$1.39
Ken GriffinCitadel Advisors
$-24.0K
ExitQ1 2025
$24k
$0.6071
$1.39
Trade ABVC

About ABVC BioPharma, Inc.

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

CEO
Uttam Yashwant Patil
IPO Date
Nov 10, 2004

Market Data

VolumeTotal shares traded during the current trading session.
232K

Valuation

Market CapCompany equity value based on share price multiplied by shares outstanding.
$19M

Financials

Financial statement snapshot is not available yet.

Modern Market Industries

AI & Compute

  • Semiconductors & Accelerators
  • Cloud & AI Platforms
  • Data Center & Networking

Software & Digital

  • Enterprise Software
  • Cybersecurity
  • DevTools & Observability
  • Consumer Internet & Marketplaces
  • Digital Advertising & Media

Healthcare

  • GLP-1 & Metabolic Health
  • Biotech & Oncology
  • Medical Devices & Diagnostics
  • Healthcare Services
  • Pharmaceuticals

Finance & Energy

  • Banks & Capital Markets
  • Asset Management & Exchanges
  • Insurance
  • Payments & Fintech
  • Digital Assets
  • Oil, Gas & Fuels

Modern categories

  • AI & Compute Infrastructure
  • Software & Digital Platforms
  • Healthcare Innovation
  • Financial Infrastructure
  • Energy & Grid

Detailed industries

  • Semiconductors & Accelerators
  • Cloud & AI Platforms
  • Data Center & Networking
  • Enterprise Software
  • Cybersecurity
  • DevTools & Observability
  • Consumer Internet & Marketplaces
  • Digital Advertising & Media

Action types

  • Investor actions
  • Insider Trades
  • Congress Trades
  • Stocks

Browse

  • Archive
  • Industries
  • Categories
  • Investors
  • Watchlist
© 2026 TradingNote
ArchiveIndustriesCategoriesInvestorsWatchlist